Anavex Life Sciences logo

Anavex Life SciencesNASDAQ: AVXL

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

02 August 2006

Next earnings report:

27 November 2024

Last dividends:

N/A

Next dividends:

N/A
$580.00 M
-67%vs. 3y high
67%vs. sector
-vs. 3y high
-vs. sector
-61%vs. 3y high
80%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 23:40:42 GMT
$6.84+$0.04(+0.59%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

AVXL Latest News

Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024
globenewswire.com31 October 2024 Sentiment: POSITIVE

Data of Blarcamesine confirm upstream SIGMAR1 activation Presented as Late Breaking Oral Communications at Clinical Trials on Alzheimer's Disease (CTAD) Conference 2024 Oral, once daily blarcamesine meaningfully slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today presented new data from the Phase IIb/III study showing that blarcamesine (ANAVEX®2-73), once daily orally, demonstrates pre-specified clinical efficacy through upstream SIGMAR1 activation. Clinical data confirmed the mechanism of action (MoA) by pre-specified SIGMAR1 gene analysis in people with early Alzheimer's disease (AD).

Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
globenewswire.com17 October 2024 Sentiment: POSITIVE

Part A of the placebo-controlled Phase 2 study has been completed ANAVEX®3-71 demonstrates a dose-dependent pharmacodynamic effect on objective EEG biomarkers of schizophrenia Patients are currently being dosed in Part B of the Phase 2 study which will investigate a longer treatment duration NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced encouraging preliminary electroencephalography (EEG) biomarker results from the Part A of the ongoing placebo-controlled Phase 2 clinical study of ANAVEX®3-71 for the treatment of schizophrenia. Part A of the Phase 2 study ANAVEX®3-71-SZ-001 (NCT06245213), was a multiple ascending dose study in 16 participants treated with either oral placebo, oral ANAVEX®3-71 90 mg daily, or oral ANAVEX®3-71 180 mg daily for 10 days.

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update
globenewswire.com06 August 2024 Sentiment: NEUTRAL

Company to host a webcast today at 8:30 a.m. Eastern Time

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024
globenewswire.com01 August 2024 Sentiment: NEUTRAL

Webcast and Conference Call To be Held Tuesday, August 6, 2024, 8:30 am ET Webcast and Conference Call To be Held Tuesday, August 6, 2024, 8:30 am ET

Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference
globenewswire.com28 July 2024 Sentiment: POSITIVE

Oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events

Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
globenewswire.com20 June 2024 Sentiment: POSITIVE

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference being held June 27, 2024.

Anavex Life Sciences (AVXL) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Investment Research15 May 2024 Sentiment: POSITIVE

Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), indicating increased confidence in the company's earnings potential. This could lead to a rise in the stock price in the short run.

Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
GlobeNewsWire25 March 2024 Sentiment: POSITIVE

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference, April 8 – 11, 2024. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company scheduled at 8:45 AM (ET) on Monday, April 8th, 2024.

Anavex Life Sciences Corp. (AVXL) Q1 2024 Earnings Call Transcript
Seeking Alpha07 February 2024 Sentiment: POSITIVE

Anavex Life Sciences Corp. (AVXL) Q1 2024 Earnings Call Transcript

GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance
Zacks Investment Research31 January 2024 Sentiment: POSITIVE

GSK's revenues benefit from strong growth across all segments, especially the Shingles and RSV vaccines. The company also issues fresh 2024 guidance for all its segments.

  • 1(current)
  • 2

What type of business is Anavex Life Sciences?

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

What sector is Anavex Life Sciences in?

Anavex Life Sciences is in the Healthcare sector

What industry is Anavex Life Sciences in?

Anavex Life Sciences is in the Biotechnology industry

What country is Anavex Life Sciences from?

Anavex Life Sciences is headquartered in United States

When did Anavex Life Sciences go public?

Anavex Life Sciences initial public offering (IPO) was on 02 August 2006

What is Anavex Life Sciences website?

https://www.anavex.com

Is Anavex Life Sciences in the S&P 500?

No, Anavex Life Sciences is not included in the S&P 500 index

Is Anavex Life Sciences in the NASDAQ 100?

No, Anavex Life Sciences is not included in the NASDAQ 100 index

Is Anavex Life Sciences in the Dow Jones?

No, Anavex Life Sciences is not included in the Dow Jones index

When was Anavex Life Sciences the previous earnings report?

No data

When does Anavex Life Sciences earnings report?

The next expected earnings date for Anavex Life Sciences is 27 November 2024